“By helping identify cancer recurrences as early as possible, StrataMRD has tremendous potential to change how we care for patients after initial cancer treatment,” says Dr.
#Strata oncology trial
The trial is a test of the Strata SentinalMRD, a minimal residual disease test that has the potential to shift the paradigm of cancer care, bringing the use of biomarker-matched precision therapies to earlier stages of the disease, the company says.
is expanding the clinical trial of its Sentinel early cancer treatment with the addition of University of Michigan’s Rogel Cancer Center and the Lehigh Valley Topper Cancer Institute (LVTCI) in Pennsylvania. Courtesy of LVTCIĪnn Arbor-based Strata Oncology Inc. Any other clinically significant medical condition that, in the opinion of the treating physician, makes participation undesirable, including but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness.Lehigh Valley Topper Cancer Institute in Pennsylvania (pictured), and the Rogel Cancer Center at U-M are joining Strata Oncology’s trial of its SentinelMRD test.Medical condition that would place the patient at risk as a result of blood donation, such as bleeding disorder.Participant has a known history of human immunodeficiency virus (HIV), Hepatitis B or known active Hepatitis C virus infection.History of stroke including transient ischemic attack (TIA) or acute myocardial infarction within 6 months of consent.Ongoing peripheral neuropathy of CTCAE grade ≥3.Ongoing toxicity of CTCAE grade ≥2, other than peripheral neuropathy, related to cancer treatment that was completed within 4 weeks of consent.Females who are pregnant or nursing or plan to become pregnant or anyone unwilling to use contraception for the duration of treatment.Has received a systemic cancer treatment within 3 weeks of first study dose.Major surgery within 4 weeks prior to study entry.Adequate cardiac function: 8.1) Left ventricular ejection fraction (LVEF) ≥ 50%, 8.2) QTc interval ≤ 470 ms (females) or ≤ 450 ms (males) average preferredĪn individual who meets any of the following criteria will be excluded from participation in this study:.Adequate bone marrow, organ function & laboratory parameters as determined by the treating physician.
0 kommentar(er)
